Viatris Inc

Stock Chart, Company Information, and Scan Results

$10.41(as of Aug 28, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Viatris Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$10.41
Ticker SymbolVTRS
ExchangeNasdaq
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees32,000
CountyUSA
Market Cap$12,148.4M
EBIDTA4,112.9M
10-Day Moving Average10.51
P/E Ratio-3.52
20-Day Moving Average9.98
Forward P/E Ratio4.63
50-Day Moving Average9.39
Earnings per Share-2.93
200-Day Moving Average9.82
Profit Margin-0.13%
RSI65.05
Shares Outstanding1,165.9M
ATR0.25
52-Week High13.04
Volume6,200,170
52-Week Low6.68
Most Recent Support Level10.43
Book Value15,570.5M
Most Recent Resistance Level10.82
P/B Ratio0.78
Upper Keltner10.55
P/S Ratio0.87
Lower Keltner9.42
Debt-to-Equity Ratio10.55
Next Earnings Date11/10/2025
Cash Surplus-1,114.3M
Next Ex-Dividend DateUnknown

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. It has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Viatris Inc In Our Stock Scanner

As of Aug 29, 2025
example chart graphic
Scan Name: Low PS RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Dragonfly DojiScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Doji CandlesScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Uptrending StocksScan Type: Chart Pattern Scans
As of ---
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.